Results 121 to 130 of about 15,000 (182)

Current Evidence on the Protective Effects of Recombinant Human Erythropoietin and Its Molecular Variants against Pathological Hallmarks of Alzheimer's Disease. [PDF]

Pharmaceuticals (Basel), 2020
Jarero-Basulto JJ, Rivera-Cervantes MC, Gasca-Martínez D, García-Sierra F, Gasca-Martínez Y, Beas-Zárate C.   +5 more
europepmc   +1 more source

Does recombinant human erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects? [PDF]

J Med Virol, 2020
Hadadi A, Mortezazadeh M, Kolahdouzan K, Alavian G.   +3 more
europepmc   +1 more source

Intranasal injection of recombinant human erythropoietin improves cognitive and visual impairments in chronic cerebral ischemia rats. [PDF]

Biomed Rep, 2020
Zhou Y, Sun B, Guo J, Zhou G.
europepmc   +1 more source

[Recombinant human erythropoietin].

Revista da Associacao Medica Brasileira (1992), 1993
openaire   +1 more source

Effects of recombinant human erythropoietin

Journal of Equine Veterinary Science, 1999
openaire   +1 more source

[The pharmacokinetics of recombinant human erythropoietin].

Terapevticheskii arkhiv, 1995
V N, Siniukhin, E A, Stetsiuk, E V, Lovchinskiĭ, S V, Lebedev, I S, Iarmolinskiĭ, V V, Liakhov   +5 more
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Benefits of recombinant human erythropoietin

Lancet, The, 2002
I, Cavill, J D, Williams
exaly   +3 more sources

Recombinant Human Erythropoietin

DICP, 1989
Erythropoietin is produced mainly by the kidneys and stimulates erythropoiesis in the bone marrow. Chronic renal failure is characterized by anemia, which is principally caused by erythropoietin deficiency. Recombinant human erythropoietin (r-hEPO) corrects the anemia of chronic renal disease and improves patient well-being, exercise tolerance, and ...
M H, Schwenk, C E, Halstenson
  +7 more sources

Intraperitoneal Administration of Recombinant Human Erythropoietin

Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 1992
Objective To determine the efficacy and safety of intraperitoneal administration of recombinant human erythropoietin (rHuEPO) in continuous ambulatory peritoneal dialysis (CAPD) patients compared to subcutaneous rHuEPO.
Frenken, L. A., Struijk, D. G., Coppens, P. J., Tiggeler, R. G., Krediet, R. T., Koene, R. A.   +5 more
openaire   +3 more sources